Lista de obras - Miles C Andrews - Dominio Público Uruguay

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme

artículo científico publicado en 2014

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

artículo científico publicado en 2022

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

artículo científico publicado en 2018

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

artículo científico publicado en 2013

Cancer Evolution during Immunotherapy.

artículo científico publicado en 2017

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma

artículo científico publicado en 2015

Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation

artículo científico publicado en 2022

Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

scientific article published on 21 October 2019

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.

artículo científico publicado en 2018

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

artículo científico publicado en 2017

Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells

artículo científico publicado en 2014

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

artículo científico publicado en 2016

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

artículo científico publicado en 2017

Evolving role of tumor antigens for future melanoma therapies.

artículo científico publicado en 2014

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

artículo científico publicado en 2017

Hallmarks of response to immune checkpoint blockade

artículo científico publicado en 2017

Human perforin mutations and susceptibility to multiple primary cancers

artículo científico publicado en 2013

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

artículo científico publicado en 2014

Immunotherapy resistance: the answers lie ahead - not in front - of us.

artículo científico publicado en 2017

Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma

artículo científico publicado en 2016

MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

artículo científico publicado en 2014

MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells.

artículo científico publicado en 2013

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

artículo científico publicado en 2018

Nitric oxide donation lowers blood pressure in adrenocorticotrophic hormone-induced hypertensive rats.

artículo científico publicado en 2004

Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib

artículo científico publicado en 2016

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

artículo científico publicado en 2017

Patterns of care for metastatic renal cell carcinoma in Australia.

artículo científico

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

artículo científico publicado en 2017

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.

artículo científico publicado en 2014

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

artículo científico publicado en 2020

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

artículo científico publicado en 2020

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

scientific article published on 03 September 2019

Systems analysis identifies miR-29b regulation of invasiveness in melanoma.

artículo científico publicado en 2016

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

artículo científico publicado en 2017

The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression

artículo científico publicado en 2018

The good, the (not so) bad and the ugly of immune homeostasis in melanoma.

artículo científico publicado en 2018

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

artículo científico publicado en 2014

The nitric oxide system in glucocorticoid-induced hypertension

artículo científico publicado en 2002

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy

artículo científico publicado en 2015

Lista de obras de Miles C Andrews

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Cancer Evolution during Immunotherapy.

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma

Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation

Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Evolving role of tumor antigens for future melanoma therapies.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Hallmarks of response to immune checkpoint blockade

Human perforin mutations and susceptibility to multiple primary cancers

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Immunotherapy resistance: the answers lie ahead - not in front - of us.

Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma

MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Nitric oxide donation lowers blood pressure in adrenocorticotrophic hormone-induced hypertensive rats.

Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Patterns of care for metastatic renal cell carcinoma in Australia.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Systems analysis identifies miR-29b regulation of invasiveness in melanoma.

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression

The good, the (not so) bad and the ugly of immune homeostasis in melanoma.

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

The nitric oxide system in glucocorticoid-induced hypertension

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy